Regulators

ALS Biomarkers Are Entering the Approval Fight

The first oral PCSK9 inhibitor is approved. A pill will not fix cholesterol access by itself

Oral GLP-1 drugs could widen access, but high prices may do the opposite

Boehringer Ingelheim is adding a third target to obesity treatment.

Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.

The Cyclospora Test Was Wrong. Public Trust Cannot Be

China Just Put a Bispecific ADC Into Esophageal Cancer

Prevention Is Now Alzheimer’s Hardest Trial

Microglia Are Not a Shortcut to Alzheimer’s Certainty
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
